BridgeBio Pharma Price To Earning vs. Operating Margin
| BBIO Stock | USD 34.35 1.90 5.24% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.7 | 0.9825 |
|
|
For BridgeBio Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BridgeBio Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BridgeBio Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BridgeBio Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BridgeBio Pharma over time as well as its relative position and ranking within its peers.
BridgeBio |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Revenue Per Share | Quarterly Revenue Growth 2.371 | Return On Assets | Return On Equity |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BridgeBio Pharma Operating Margin vs. Price To Earning Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BridgeBio Pharma's current stock value. Our valuation model uses many indicators to compare BridgeBio Pharma value to that of its competitors to determine the firm's financial worth. BridgeBio Pharma is rated below average in price to earning category among its peers. It is rated below average in operating margin category among its peers . At this time, BridgeBio Pharma's Operating Profit Margin is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BridgeBio Pharma's earnings, one of the primary drivers of an investment's value.BridgeBio Operating Margin vs. Price To Earning
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
BridgeBio Pharma |
| = | (13.72) X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
BridgeBio Pharma |
| = | (37.63) % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
BridgeBio Operating Margin Comparison
BridgeBio Pharma is currently under evaluation in operating margin category among its peers.
BridgeBio Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BridgeBio Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BridgeBio Pharma will eventually generate negative long term returns. The profitability progress is the general direction of BridgeBio Pharma's change in net profit over the period of time. It can combine multiple indicators of BridgeBio Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 8 K | 8.4 K | |
| Net Interest Income | -82 M | -77.9 M | |
| Interest Income | 17.2 M | 18.1 M | |
| Operating Income | -593 M | -622.6 M | |
| Net Loss | -543.3 M | -570.5 M | |
| Income Before Tax | -542.2 M | -569.3 M | |
| Total Other Income Expense Net | 50.8 M | 53.3 M | |
| Net Loss | -433.1 M | -454.7 M | |
| Net Loss | -543.3 M | -570.5 M | |
| Income Tax Expense | 1.2 M | 1.1 M | |
| Non Operating Income Net Other | 124.2 M | 130.4 M | |
| Change To Netincome | 129.6 M | 136.1 M | |
| Net Loss | (2.88) | (3.02) | |
| Income Quality | 0.96 | 0.69 | |
| Net Income Per E B T | 0.99 | 0.74 |
BridgeBio Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BridgeBio Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BridgeBio Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BridgeBio Pharma's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in BridgeBio Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Analyst Advice Now
Analyst AdviceAnalyst recommendations and target price estimates broken down by several categories |
| All Next | Launch Module |
Use Investing Themes to Complement your BridgeBio Pharma position
In addition to having BridgeBio Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Staples ETFs Thematic Idea Now
Consumer Staples ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Consumer Staples ETFs theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Staples ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
To fully project BridgeBio Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of BridgeBio Pharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BridgeBio Pharma's income statement, its balance sheet, and the statement of cash flows.